Press time:2021-10-08From:CR Pharma [ Font:BigMediumSmall]
On October 7, a delegation led by Zhang Boli, an academician with the Chinese Academy of Engineering and recipient of the national honorary title “the People’s Hero,” was invited to visit CR Sanjiu, where he gave guidance on the operations and R&D of the pharmaceutical company.
Qiu Huawei, President of CR Sanjiu, received Zhang Boli and expressed his high regard for the academician’s outstanding contributions and hard work in the fight against COVID-19. Mr. Qiu also saluted the academician for the leadership role he had been taking in the development of traditional China medicine, as well as his support for CR Sanjiu.
During the visit, Zhang Boli got a deep understanding of China Resources Group’s history, business segments, core businesses, etc., and expressed his respect for the group’s profound love for the country. The academician pointed out that the future development of the pharmaceutical industry was quite promising as “benefit people’s lives and health” had been stated in the 14th Five-Year Plan and steady progress had been made in promoting the “Healthy China 2030” blueprint. He acknowledged CR Sanjiu’s achievements during the 13th Five-Year Plan period, and suggested that the company should continue to develop its own strengths and the self-diagnosis field in the future, and gain stronger competitive advantages in the R&D and production of high-end preparations and new excipients in particular, so as to offer consumers with OTC medications of higher quality and better experience; boost the R&D of traditional Chinese medicine, especially new Chinese patent medicines, classical prescriptions, and formula granules, and continue to carry out the secondary development of large varieties of traditional Chinese medicines; further improve intelligent manufacturing and apply advanced technologies, such as digital technologies, to enhance its capabilities of refined production.
The academician also gave explanations and guidance on the situation and policies regarding the pharmaceutical industry.
